Penumbra (PEN) Free Cash Flow Growth (3y) (2017 - 2026)
Penumbra (PEN) Free Cash Flow Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.46 Bn | 193.86 Bn | 7.27 Bn | 41.96% |
| 2 | Stryker | 127.41 Bn | 123.93 Bn | 4.50 Bn | 25.48% |
| 3 | Medtronic | 118.87 Bn | 109.65 Bn | 6.41 Bn | 0.05% |
| 4 | Boston Scientific | 73.47 Bn | 72.93 Bn | 3.85 Bn | 35.42% |
| 5 | Edwards Lifesciences | 51.95 Bn | 47.69 Bn | 1.35 Bn | 250.09% |
| 6 | Dexcom | 34.30 Bn | 32.35 Bn | 830.00 Mn | 12.01% |
| 7 | GE HealthCare Technologies | 33.76 Bn | 31.65 Bn | 2.18 Bn | 35.65% |
| 8 | Koninklijke Philips | 26.35 Bn | 23.02 Bn | 4.55 Bn | 20.87% |
| 9 | Steris | 23.04 Bn | 22.55 Bn | 684.20 Mn | 9.23% |
| 10 | Penumbra | 12.78 Bn | 12.13 Bn | 264.94 Mn | 36.64% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 36.64% |
| Mar 31, 2026 | 87.82% |
| Dec 31, 2025 | 77.56% |
| Sep 30, 2025 | 86.18% |
| Jun 30, 2025 | 33.90% |
| Mar 31, 2025 | 91.19% |
| Dec 31, 2024 | 55.85% |
| Sep 30, 2024 | 14.66% |
| Jun 30, 2024 | 138.84% |
| Mar 31, 2024 | 55.62% |
| Dec 31, 2023 | 173.35% |
| Sep 30, 2023 | 38.10% |
| Jun 30, 2023 | 37.73% |
| Mar 31, 2023 | 39.37% |
| Dec 31, 2022 | 45.59% |
| Sep 30, 2022 | -40.27% |
| Jun 30, 2022 | -133.76% |
| Mar 31, 2022 | -47.89% |
| Dec 31, 2021 | -73.84% |
| Sep 30, 2021 | 33.67% |